June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
APC-Coated Intraocular Lenses Reduce the Occurrence of PCO in a Human Anterior Chamber Model
Author Affiliations & Notes
  • Raffael Liegl
    Ophthalmology, Ludwig-Maximilians-University Munich, Muenchen, Germany
  • Christian Wertheimer
    Ophthalmology, Ludwig-Maximilians-University Munich, Muenchen, Germany
  • Marcus Kernt
    Ophthalmology, Ludwig-Maximilians-University Munich, Muenchen, Germany
  • Armin Wolf
    Ophthalmology, Ludwig-Maximilians-University Munich, Muenchen, Germany
  • Anselm Kampik
    Ophthalmology, Ludwig-Maximilians-University Munich, Muenchen, Germany
  • Kirsten Eibl-Lindner
    Ophthalmology, Ludwig-Maximilians-University Munich, Muenchen, Germany
  • Footnotes
    Commercial Relationships Raffael Liegl, None; Christian Wertheimer, None; Marcus Kernt, Allergan (R), Novartis (R), OD-OS (C), Optos (C); Armin Wolf, None; Anselm Kampik, None; Kirsten Eibl-Lindner, PCT/EP2010/051490 (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5946. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Raffael Liegl, Christian Wertheimer, Marcus Kernt, Armin Wolf, Anselm Kampik, Kirsten Eibl-Lindner; APC-Coated Intraocular Lenses Reduce the Occurrence of PCO in a Human Anterior Chamber Model. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5946.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Posterior capsule opacification (PCO) is the most common reason for secondary visual deterioration after successful cataract surgery and occurs in more than 40% of patients ten years after surgery. Alkylphosphocholines (APC) have proven to posses properties to reduce PCO formation in vitro. This study aims to investigate the feasibility of pharmacologic PCO prophylaxis with alkylphosphocholine (APC) coated hydrophilic acrylic intraocular lenses (IOLs), a possible way of prospective application, in a human anterior chamber model (HACM) in vitro.

Methods: Four different hydrophilic acrylic intraocular lenses (IOLs) were covered with APCs. Uncoated IOLs served as controls. Proliferating human lens epithelial cells (HLE-B3) were grown in MEM with 3% FCS supplemented with 50 IU penicillin/ml and 50 µg streptomycin/ml, on PET membranes, uncoated or coated with collagen I or laminin, in cell culture inserts. APC coated and control IOLs were then each placed on top. After 5 days of cultivation under standard cell culture conditions, the Tetrazolium Dye Reduction Assay (MTT) was performed and the optical density was assessed (ELISA) to calculate the number of vital cells per well and the area of cell distribution in percent control. Each experiment was performed in duplicate and repeated three times (n = 12 for each setting).

Results: APC coated IOLs inhibit human lens epithelial cell proliferation significantly in terms of the total number of proliferating cells as well as the central cell distribution. There was also a difference between uncoated cell culture inserts compared to coated ones (in % control): We found a reduction of 25%±18 for uncoated compared to 48%±23 for coated inserts in terms of the total cell number and also a decrease in cell distribution on PET membranes of 32%±12 (uncoated) and 45%±17 (coated) respectively. The ability of APC coated IOLs to inhibit HLE-B3 cell proliferation in vitro was best on IOLs with a water content of 28 %.

Conclusions: We could demonstrate that APC coated IOLs are effective inhibitors of human lens epithelial cell proliferation in the presence of ECM components in a HACM of PCO. APCs ability to reduce major components of PCO formation in vitro together with their chemical properties making them suitable coating agents for hydrophilic acrylic IOLs show that APCs could become a valuable IOL coating agent for the prevention of PCO.

Keywords: 445 cataract  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×